Journal of Controversies in Biomedical Research 2015; 1(1):40-50.
Doi: http://dx.doi.org/10.15586/jcbmr.2015.9
Review Article
Anticoagulation for Atrial Fibrillation in End-stage Kidney Disease
Gavin Lee1, David W Johnson1,2,3
1Department of Nephrology, Princess Alexandra Hospital, Brisbane, Australia; 2School of Medicine, The University of Queensland, Brisbane, Australia; 3Translational Research Institute, Brisbane, Australia.
Abstract
Atrial
fibrillation (AF) is the most common arrhythmia in the general
population and it has been found to have a higher prevalence in
end-stage kidney disease (ESKD). It is associated with a higher risk of
stroke and mortality compared to those without AF. Patients with
ESKD have generally been excluded from randomized controlled trials
(RCTs) evaluating the efficacy of anticoagulation in reduction of
stroke risk. Current observational evidence for anticoagulation for AF
in the ESKD population has yielded conflicting results, but in
aggregate favours a lack of benefit in stroke risk reduction with an
increase in bleeding risk. There are also reports that warfarin use in
ESKD patients on dialysis is associated with greater International
Normalised Ratio (INR) variability and increased risk of vascular
calcification and calciphylaxis (uraemic calcific arteriolopathy). RCTs
are required to assess the net clinical benefit of anticoagulation in
this group.
Received: 20 September 2015; Accepted after revision: 19 October 2015; Published: 29 October 2015.
Author
for correspondence: Professor
David W Johnson, Department of Nephrology, Level 2, ARTS Building,
Princess Alexandra Hospital, Ipswich Road, Woolloongabba, Brisbane, Qld
4102, Australia. E-mail: [email protected]
How
to cite: Lee G, Johnson DW. Anticoagulation for atrial fibrillation in end-stage kidney disease. Journal of
Controversies in
Biomedical Research 2015; 1(1):40-50. Doi: http://dx.doi.org/10.15586/jcbmr.2015.9
Licence: This open access article is licenced under Creative Commons Attribution 4.0 International (CC BY 4.0). http://creativecommons.org/licenses/by/4.0/
Introduction
Atrial
fibrillation (AF) is the most common arrhythmia in the general population, and
the incidence is appreciably higher in patients with end-stage kidney disease
(ESKD). A meta-analysis of twenty-five studies found the prevalence of AF in
ESKD patients to be 11.6% and overall incidence to be 2.7/100 patient years
(1). The prevalence appears to be
increasing over time, with one analysis from the United States Renal Data System
(USRDS) showing a three-fold increase in prevalence from 1992 to 2006 (2). This
may reflect the increasing age and comorbidity burden in the dialysis
population. The risks of mortality and stroke are significantly increased in
ESKD patients with AF (26.9 and 5.2 per 100 patient-years, respectively)
compared to those without (13.4 and 1.9 per 100 patient-years) (1). In the
general population, systemic anticoagulation is typically indicated for
reduction of stroke risk (3), but the benefit-to-risk ratio is uncertain in the
ESKD population given the lack of randomized controlled trial (RCT) evidence.
In this review, we will discuss the observational data pertaining to the effect
of warfarin on stroke and bleeding risk in ESKD patients and the need for a high
quality RCT to address this controversial issue.
Risk of AF in CKD
The
prevalence of AF in the general population is approximately 1%, although it
appears to increase markedly with advancing age to a prevalence of 9-18% in
individuals aged 80 years or older (4, 5). Patients with ESKD on dialysis are
reported to have a prevalence of AF from 7-27% (6-9). Many of the risk factors for AF in the
general population are also common in the dialysis population, including obesity,
hypertension and heart failure (10). The inverse relationship between AF and
renal function has been demonstrated in several population-based studies (11,
12). The Atherosclerosis Risk in Communities (ARIC) study found hazard ratios
of 1.3, 1.6 and 3.2 in patients with cystatin C-based estimated glomerular
filtration rate (eGFR) values of 60-89, 30-59 and 15-29mL/min, respectively,
compared to the reference population (eGFR >/= 90mL/min) (11). The Reasons for
Geographic and Racial Differences in Stroke (REGARDS) study similarly reported
age-, race- and sex-adjusted odds ratios for prevalent AF to be 2.67, 1.68 and
3.52 for those with stage 1 to 2, stage 3 and stage 4 to 5 chronic kidney
disease (CKD), respectively (12).
Stroke risk in AF in the
dialysis population
CKD
has been shown to be a risk factor for stroke in several studies. Holzmann et
al. performed a very large longitudinal study of 539287 patients with 12 years
of follow-up, and found an increase in ischaemic stroke risk with worsening CKD
(HR 1.09, 95% CI 1.04-1.14 for stage 2 CKD; HR 1.24, 95% CI 1.10-1.39 for stage
3 CKD and HR 2.27, 95% CI 1.63-2.27 for stage 4 CKD) (13). In a USRDS report,
the annual stroke incidences in matched non-CKD, CKD and HD patients were 2.6%,
9.6% and 15.1%, respectively (14).
In
the general population, the absolute risk of stroke can be estimated with the
CHADS2 score, or more recently the CHA2DS2-VASc score (15). The CHA2DS2-VASc
score can be calculated by assigning points for Congestive heart failure (1
point); Hypertension (1 point); Age ≥75 years (2 points); Diabetes mellitus (1
point); prior Stroke, transient ischaemic attack or thromboembolism (2 points),
Vascular disease (1 point), Age 65-74 years (1 point) and Sex category (female
1 point).
In
the absence of a specific tool validated to assess stroke risk in the dialysis
population, several studies have suggested a correlation between higher CHADS2
score and stroke risk in this group (8, 16-18). Olesen et al. found the
unadjusted incidence of stroke to be 1.99, 2.35 and 3.55 events per 100
person-years in dialysis patients with CHADS2 scores of 0, 1 and 2,
respectively (16). Of note, the stroke
risk in every category of CHADS2 score was higher than a comparison group of
non-dialysis patients with AF, suggesting the CHADS2 score may underestimate
stroke risk in dialysis patients.
Warfarin in dialysis
patients
Warfarin
(Wisconsin Alumni Research Foundation coumARIN) is a vitamin K antagonist that
inhibits vitamin K epoxide reductase, interfering with the production of
vitamin K-dependent coagulation factors II, VII, IX and X, protein C and
protein S (19). There is reasonable evidence that warfarin may accelerate
vascular calcification in dialysis patients, potentially via antagonism of the
vitamin K-dependent matrix G1a protein (MGP), a potent inhibitor of vascular
calcification. Mice that lack MGP were found to die within two months of birth
due to severe arterial calcification leading to vessel rupture (20). In humans,
a loss-of-function mutation in the gene encoding MGP (Keutel syndrome) leads to
widespread large vessel vascular calcification and abnormal cartilage
calcification (21).
The
effect of warfarin on MGP and vascular calcification has been demonstrated in a
mouse model, where administration of warfarin was found to induce arterial
medial calcification, associated with a reduction in MGP mRNA expression, which
could be reversed with vitamin K treatment (22). McCabe et al. (23) similarly
reported increased vascular calcification in rats with CKD on warfarin, which
was also blunted by vitamin K. In a retrospective study of 108 haemodialysis
(HD) patients, an association was found between duration of warfarin exposure
and degree of aortic valve calcification after adjustment for dialysis vintage,
calcium and calcitriol intake (24). Furthermore, a recent Japanese study found
an 11-fold risk in HD patients on warfarin for calciphylaxis (uraemic calcific
arteriolopathy), an uncommon complication of ESKD characterised by skin
ulceration and necrosis with small vessel medial calcification and intimal
proliferation (25).
The
time in therapeutic range (TTR) of the international normalised ratio (INR) is
an important predictor of warfarin efficacy and safety in the general
population (26). A systematic review of 47 studies reporting INR control found
approximately 60% of INR measurements to be within the therapeutic range (27).
Patients on HD tend to have lower warfarin dose requirements and greater INR
variability (28). To further add to this unpredictability, anticoagulation
catheter-locking solutions may interfere with INR measurement when samples are
collected from the catheter directly (29). Two studies have attempted to reduce
INR variability with daily low-dose vitamin K supplementation (30) and
thrice-weekly post-HD warfarin dosing (31). Both interventions were associated
with modest improvements in TTR but their effects on bleeding risk remained
unclear.
Uncertainty of warfarin
net benefit
Warfarin
and, to a lesser extent, antiplatelet agents have been found to reduce the
stroke risk in patients with AF. A 2007 meta-analysis of 29 trials including
28044 patients found relative reductions in stroke risk of 64% with warfarin
and 22% with antiplatelet agents (3). The 2014 ACC/AHA (American College of
Cardiology/American Heart Association) guideline for management of patients
with atrial fibrillation recommends oral anticoagulation if the CHA2DS2-VASc
score is two or greater (32). The
guideline extends this recommendation to patients with ESKD on haemodialysis.
However, there have been no RCTs (RCTs) investigating the benefit of
anticoagulation for stroke risk in the ESKD population, who have largely been
excluded from the trials in the general population. Consequently, the Kidney
Disease Improving Global Outcomes (KDIGO) Guidelines (33, 34) caution that,
given the lack of RCTs, the risk-to-benefit ratio of routine anticoagulation
for primary or secondary prevention of stroke remains uncertain. More recently,
the International Society for Peritoneal Dialysis (ISPD) Cardiovascular Guidelines
suggest “individualization of warfarin prescription for prevention of stroke in
peritoneal dialysis patients with atrial fibrillation in view of an increased
risk of bleeding and uncertain effects on cerebrovascular outcomes. (2D)” (35,
36).
Clinical
equipoise exists among nephrologists regarding the benefit-to-risk ratio of
anticoagulation for stroke risk reduction in the dialysis population. A survey
of 56 Canadian nephrologists found agreement in the majority (72%) that there
was a state of uncertainty regarding this clinical question (37). Each
nephrologist was presented six clinical scenarios and given a choice as to
whether they were likely to start warfarin, unlikely to start warfarin or were
uncertain. The level of uncertainty increased when a patient was on
haemodialysis and when risk factors for bleeding were present, including a
history of gastrointestinal bleeding or a risk for falls.
Stroke and bleeding risk
with warfarin
In
the absence of a RCT addressing the net benefit of warfarin for AF in ESKD
patients, the best available data so far remains observational in nature. Chan
et al. performed a retrospective cohort analysis of 1671 incident HD patients
with atrial fibrillation followed up for a mean of 1.6 years (38). The use of
warfarin was associated with an increased risk of stroke (hazard ratio [HR]
1.93, 95% CI 1.29-2.90) after Cox regression analysis, and propensity matching
did not significantly affect the findings of the analysis. There was a
four-fold increase in mortality from stroke (p=0.009) and increase in
hospitalisation from stroke (HR 1.89, 95% CI 1.16-3.09), but no significant
difference in rates of hospitalisation for bleeding (HR 1.04, 95% CI
0.73-1.46). The classification of haemorrhagic stroke as a stroke outcome in
this study may have partially accounted for the reported increase in stroke
risk.
Wizemann
et al. sampled 2188 patients with AF out of 17513 HD patients from the
international Dialysis Outcomes and Practice Patterns Study (DOPPS) (8). They
found a significant association between warfarin and increased stroke risk in
patients aged over 75 years, with reported hazard ratios of 1.29 (95% CI
0.45-3.68), 1.35 (95% CI 0.69-2.63) and 2.17 (95% CI 1.04-4.53) in the patient
groups aged <65, 66-75 and >75 respectively. Patients with a CHADS2 score
of 3 or greater on warfarin were also found to have higher stroke risk,
although this finding was explained by the age component of the score rather
than the other variables. Bleeding risk data were not provided in this study.
Phelan
et al. compared stroke and bleeding risks in 141 HD patients on warfarin, 704 HD
patients not on warfarin and 3266 non-dialysis patients on warfarin (28). In
the patients with AF, the HD warfarin group had a higher risk of ischaemic
stroke than the non-dialysis warfarin group (2.2 vs 0.4 events per 100
person-years, p=0.024). The incidence of major haemorrhage per 100
patient-years was significantly greater in the HD warfarin group (10.8)
compared to 2.1 in the non-HD warfarin group (p<0.001), but similar to the
HD non-warfarin group (8.0, p=0.593).
In
contrast, Winkelmayer et al. evaluated outcomes in HD patients with incident AF
rather than pre-existing AF by use of an inception cohort of older patients
aged 66 years or older at the time of dialysis commencement (39). They
identified 2313 patients with new AF who survived at least 30 days from
discharge, and compared 237 patients started on warfarin within 30 days of
discharge with 948 propensity-matched patients not on warfarin. There was no
significant difference in ischaemic stroke risk (HR 0.92, 95% CI 0.61-1.37) but
the risk of haemorrhagic stroke was doubled in the warfarin group (HR 2.38, 95%
CI 1.15-4.96). The use of an inception cohort and new-user design may have
reduced bias related to variations in risk with disease duration or medication
(40), which may have accounted for the difference in reported ischaemic stroke
risk compared to the previous three studies. The risk of mortality and
gastrointestinal bleeding was similar between the two groups. The unexpected
lack of association between warfarin and increased gastrointestinal bleeding
risk may have been explained by the wide use of gastroprotective medication in
the cohort, with 70% of patients being on a proton-pump inhibitor or
histamine-2 antagonist.
Olesen
et al. searched Danish national registries to identify 901 patients requiring
renal replacement therapy (RRT) discharged from hospital with a diagnosis of
nonvalvular atrial fibrillation between 1997 and 2008 (16). Warfarin use was
associated with a lower risk of stroke or systemic thromboembolism (HR 0.44,
95% CI 0.26-0.74, p=0.002), but was not associated with bleeding risk (HR 1.27,
95% CI 0.91-1.77, p=0.15). The finding of reduced stroke risk may have been
explained by the inclusion in the study group of peritoneal dialysis (PD)
patients and kidney transplant recipients, who may have had different
risk-to-benefit profiles on warfarin compared to HD patients. Alternatively,
the results may have been confounded by indication.
Wakasugi
et al. performed a prospective multicenter cohort study of 60 Japanese HD
patients with chronic sustained AF (18). They found no difference in the
incidence of new ischaemic stroke between 28 warfarin users and 32 non-warfarin
users (HR 3.36, 95% CI 0.94-11.23) after adjustment for CHADS2 score. There was
also no difference in major bleeding risk (HR 0.85, 95% CI 0.19-3.64) or
all-cause mortality (HR 1.00, 95% CI 0.40-2.52). Although the sample size was
limited, this study provides further evidence towards the lack of benefit of
warfarin for stroke risk in HD patients with AF.
Shah
et al. conducted a population based retrospective cohort study of 1626 Canadian
dialysis (HD and PD) patients aged 65 years or older admitted to hospital with
a diagnosis of AF (17). After adjustment for potential confounders, warfarin was
not associated with risk of stroke (HR 1.14, 95% CI 0.78-1.67) but was
associated with higher bleeding risk (HR 1.44, 95% CI 1.13-1.85). Although this
study had a large sample size, a major limitation was the inclusion criterion
used to identify dialysis patients, defined as patients who had undergone three
or more haemodialysis or peritoneal dialysis procedures in the prior year,
which may have included a significant number of patients with acute kidney
injury. Furthermore, patients were assigned to the warfarin group if they
filled a prescription for warfarin in the first 30 days after discharge, and
the duration of warfarin use was not captured.
A
meta-analysis by Li et al. (41) of six observational cohort studies (8, 16-18,
38, 39) provides the highest level of evidence so far until a RCT can be
implemented. For the assessment of stroke risk, a total of 9816 participants
from the six studies were included with 2466 of these patients on warfarin. No
significant association was observed between warfarin use and the risk of stroke
(HR 1.23, 95% CI 0.80-1.87, p=0.347), although the validity of this result is
questionable in view of the statistically significant, high-level trial
heterogeneity that was identified (I2=79.2%, p=0.000). A subgroup analysis of
the four trials that included only HD patients found an increase in stroke risk
with warfarin use (HR 1.57, 95% CI 1.09-2.25, p=0.015). For the assessment of
bleeding risk, a total of 6571 patients in five studies were included with 1957
of these patients on warfarin. The fixed-effects model was used due to the
absence of significant heterogeneity (I2=20.4%, p=0.285) and found that
warfarin significantly increased bleeding risk (HR=1.20, 95% CI 1.03-1.39,
p=0.019).
Although
the accumulating evidence suggests an absence of benefit for stroke risk for
ESKD patients on warfarin and perhaps even an increased stroke risk in HD
patients, several limitations exist. Due to the observational nature of the
data, indication bias with residual confounding cannot be excluded. Patients on
warfarin were likely to have a higher risk of stroke, as assessed by their
clinician, and this may not have been fully adjusted for by covariates. The use
of registry data may have led to ascertainment bias, whereby more severe stroke
or bleeding events were preferentially recorded. Previous warfarin use was not
ubiquitously recorded and patients who had previously ceased warfarin therapy
due to a bleeding event may have been included in the non-warfarin group.
Finally, there was significant heterogeneity in stroke risk among the six
studies included in the meta-analysis, which may be accounted for by
differences in study design, study population and covariate adjustment.
Use of newer
anticoagulants
The
novel oral anticoagulants include the direct thrombin inhibitor, dabigatran,
and the factor Xa inhibitors, apixaban and rivaroxaban. Several recent large
RCTs have shown these agents to be non-inferior to warfarin for stroke risk
reduction in patients with AF (42-44). The use of these drugs in ESKD patients
appears to be steadily rising, with one recent study by Chan et al. reporting
5.9% of anticoagulated HD patients on dabigatran or rivaroxaban (45). Despite
this, there are significant concerns with the use of the novel anticoagulants
in ESKD. Firstly, patients with moderate to severe CKD have generally been
excluded from these trials, so there are no data to support the efficacy of
these agents in this population. Secondly, there are no effective options for
anticoagulation reversal in the setting of major bleeding or requirement for an
urgent surgery, except for dabigatran, for which idarucizumab has been found to
rapidly and effectively reverse the anticoagulant effect (46). Finally, these
drugs are invariably excreted renally to some extent, which can lead to
accumulation in patients with CKD. The study by Chan et al. found a higher risk
of hospitalization or death from bleeding with dabigatran (HR 1.48, 95% CI
1.21-1.81) or rivaroxaban (HR 1.38, 95% CI 1.03-1.83) compared to warfarin in
anticoagulated HD patients (45).
Dabigatran
is primarily renally excreted, with 80-85% of the drug excreted unchanged in
the urine. The half-life of the drug increases from 9 hours with normal renal
function to 25-30 hours in patients with creatinine clearance <30mL/min
(47). It is dialysable, with 50-60% of the drug removed after a 4 hours of
haemodialysis (48). Rivaroxaban undergoes 33% renal excretion via proximal
tubule secretion, but is not dialysable due to 92-95% protein binding (49).
Apixaban
is 27% excreted as unchanged drug in the urine and 14% of the drug is removed
via dialysis (50). A single dose pharmacokinetic study of apixaban compared
eight HD patients with eight controls with normal renal function and found a
36% increase in area under the curve (AUC) (51). Following this study, FDA
labeling for the product changed from “no data to inform the use of patients
with creatinine clearance <15mL/min or on dialysis” to a recommended dose in
ESKD of 5mg twice daily or 2.5mg twice daily if the patient is aged over 80 years
or body weight is less than 60kg (50). However, the pharmacokinetics of
cumulative drug dosing remains to be evaluated, and there are currently no data
on bleeding risk or efficacy in this population.
Need for a RCT
Given
the uncertainty that exists regarding the benefit-to-risk ratio of
anticoagulation for AF in ESKD patients, a high-quality RCT is required to
answer this clinical question. Previous observational studies have yielded
conflicting results and in aggregate have shown no reduction in stroke risk but
an increase in bleeding risk. Although there is clear evidence for the benefit
of warfarin for stroke risk reduction in the general population (3) and
evidence that this benefit extends to stage 3 CKD (52), it cannot reasonably be
extrapolated to the ESKD group. As an example highlighting this point, another
intervention commonly used in the CKD population, HMG-CoA reductase inhibitor
(statin) therapy for cardiovascular risk reduction, was found to significantly
reduce risk of death and major cardiovascular events in patients with CKD not
requiring dialysis (53), but this benefit did not extend to patients on
dialysis (54).
Several
challenges arise in designing and implementing a RCT on warfarin use in HD.
Firstly, it may be considered unethical to randomise patients to the use of
warfarin if previous observational data have shown a clear increase in bleeding
risk without a significant benefit in stroke risk. However, there remains a
degree of uncertainty as to the net benefit, and a rigorous RCT would provide a
higher level of evidence to answer this question than the previous
observational studies (55). Secondly, nephrologists and patients may have
strong preferences for or against anticoagulation that may limit recruitment,
although in a Canadian survey of nephrologists, the majority indicated that
they would be willing to enroll their patients in such a trial (37). Finally,
funding is unlikely to come from the pharmaceutical industry as generic
warfarin is cheap and bioequivalent to brand-name warfarin (56), so it would
likely need to be sourced publicly. An alternative would be a randomised
placebo-controlled trial of one of the newer oral anticoagulants.
In
conclusion, patients with ESKD have generally been excluded from RCTs of
anticoagulation for AF, although the risks of AF and stroke have been found to
be higher in this population. Several considerations arise when prescribing
warfarin in ESKD patients, including greater INR variability and increased risk
of vascular calcification and calciphylaxis. Numerous observational studies
have failed to identify an association between warfarin use and risk of stroke,
but have identified a clear association with heightened bleeding risk. There is
a need for a RCT to answer this clinical question, although several financial
and ethical barriers need to be overcome to implement such a trial.
Conflict of Interest
David
Johnson has received consultancy fees, research funds, travel sponsorships and
speaker's honoraria from Fresenius Medical Care and Baxter Healthcare. Gavin
Lee declares no potential conflicts of interest with respect to research,
authorship and/or publication of this article.
References
1. Zimmerman D, Sood MM, Rigatto C, Holden
RM, Hiremath S, Clase CM. Systematic review and meta-analysis of incidence,
prevalence and outcomes of atrial fibrillation in patients on dialysis. Nephrol
Dial Transplant. 2012;27(10):3816-22.
http://dx.doi.org/10.1093/ndt/gfs416
PMid:23114904
2. Winkelmayer WC, Patrick AR, Liu J,
Brookhart MA, Setoguchi S. The increasing prevalence of atrial fibrillation
among hemodialysis patients. J Am Soc Nephrol . 2011;22(2):349-57.
http://dx.doi.org/10.1681/ASN.2010050459
PMid:21233416 PMCid:PMC3029907
3. Hart RG, Pearce LA, Aguilar MI.
Meta-analysis: antithrombotic therapy to prevent stroke in patients who have
nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857.
http://dx.doi.org/10.7326/0003-4819-146-12-200706190-00007
PMid:17577005
4. Go AS, Hylek EM, Phillips KA, Chang Y,
Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in
adults: national implications for rhythm management and stroke prevention: the
AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. Jama.
2001;285(18):2370-5.
http://dx.doi.org/10.1001/jama.285.18.2370
5. McManus DD, Rienstra M, Benjamin EJ. An
Update on the Prognosis of Patients With Atrial Fibrillation. Circulation.
2012;126(10):e143-e6.
http://dx.doi.org/10.1161/CIRCULATIONAHA.112.129759
PMid:22949543 PMCid:PMC3678907
6. Wetmore JB, Mahnken JD, Rigler SK,
Ellerbeck EF, Mukhopadhyay P, Spertus JA, et al. The prevalence of and factors
associated with chronic atrial fibrillation in Medicare/Medicaid-eligible
dialysis patients. Kidney Int. 2012;81(5):469-76.
http://dx.doi.org/10.1038/ki.2011.416
PMid:22189842 PMCid:PMC3891593
7. Genovesi S, Pogliani D, Faini A,
Valsecchi MG, Riva A, Stefani F, et al. Prevalence of atrial fibrillation and
associated factors in a population of long-term hemodialysis patients. Am J
Kidney Dis. 2005;46(5):897-902.
http://dx.doi.org/10.1053/j.ajkd.2005.07.044
PMid:16253730
8. Wizemann V, Tong L, Satayathum S,
Disney A, Akiba T, Fissell RB, et al. Atrial fibrillation in hemodialysis
patients: clinical features and associations with anticoagulant therapy. Kidney
Int. 2010;77(12):1098-106.
http://dx.doi.org/10.1038/ki.2009.477
PMid:20054291
9. Atar I, Konas D, Acikel S, Kulah E,
Atar A, Bozbas H, et al. Frequency of atrial fibrillation and factors related
to its development in dialysis patients. Int J Cardiol. 2006;106(1):47-51.
http://dx.doi.org/10.1016/j.ijcard.2004.12.048
PMid:16321665
10. Schnabel RB, Sullivan LM, Levy D,
Pencina MJ, Massaro JM, D'Agostino RB, Sr., et al. Development of a risk score
for atrial fibrillation (Framingham Heart Study): a community-based cohort
study. Lancet. 2009;373(9665):739-45.
http://dx.doi.org/10.1016/S0140-6736(09)60443-8
11. Alonso A, Lopez FL, Matsushita K,
Loehr LR, Agarwal SK, Chen LY, et al. Chronic Kidney Disease Is Associated With
the Incidence of Atrial Fibrillation: The Atherosclerosis Risk in Communities
(ARIC) Study. Circulation. 2011;123(25):2946-53.
http://dx.doi.org/10.1161/CIRCULATIONAHA.111.020982
PMid:21646496 PMCid:PMC3139978
12. Baber U, Howard VJ, Halperin JL,
Soliman EZ, Zhang X, McClellan W, et al. Association of Chronic Kidney Disease
With Atrial Fibrillation Among Adults in the United States: REasons for
Geographic and Racial Differences in Stroke (REGARDS) Study. Circ Arrhythm
Electrophysiol. 2010;4(1):26-32.
http://dx.doi.org/10.1161/CIRCEP.110.957100
PMid:21076159 PMCid:PMC3049935
13. Holzmann MJ, Aastveit A, Hammar N,
Jungner I, Walldius G, Holme I. Renal dysfunction increases the risk of ischemic
and hemorrhagic stroke in the general population. Ann Med. 2012;44(6):607-15.
http://dx.doi.org/10.3109/07853890.2011.582136
PMid:21612332
14. System USRD. USRDS 2005/2006/2007
Annual Data Report: Atlas of End Stage Renal Disease in the United States.
National Institutes of Diabetes and Digestive and Kidney Diseases, Besthesda,
MD: National Institutes of Health, 2005.
15. Lip GY, Nieuwlaat R, Pisters R, Lane
DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and
thromboembolism in atrial fibrillation using a novel risk factor-based
approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263-72.
http://dx.doi.org/10.1378/chest.09-1584
PMid:19762550
16. Olesen JB, Lip GY, Kamper AL, Hommel
K, Kober L, Lane DA, et al. Stroke and bleeding in atrial fibrillation with
chronic kidney disease. N Engl J Med. 2012;367(7):625-35.
http://dx.doi.org/10.1056/NEJMoa1105594
PMid:22894575
17. Shah M, Avgil Tsadok M, Jackevicius
CA, Essebag V, Eisenberg MJ, Rahme E, et al. Warfarin use and the risk for
stroke and bleeding in patients with atrial fibrillation undergoing dialysis.
Circulation. 2014;129(11):1196-203.
http://dx.doi.org/10.1161/CIRCULATIONAHA.113.004777
PMid:24452752
18. Wakasugi M, Kazama JJ, Tokumoto A,
Suzuki K, Kageyama S, Ohya K, et al. Association between warfarin use and
incidence of ischemic stroke in Japanese hemodialysis patients with chronic
sustained atrial fibrillation: a prospective cohort study. Clin Exp Nephrol.
2014;18(4):662-9.
http://dx.doi.org/10.1007/s10157-013-0885-6
PMid:24113782
19. Kruger T, Floege J. Vitamin K
antagonists: beyond bleeding. Semin Dial. 2014;27(1):37-41.
http://dx.doi.org/10.1111/sdi.12175
PMid:24400802
20. Luo G, Ducy P, McKee MD, Pinero GJ,
Loyer E, Behringer RR, et al. Spontaneous calcification of arteries and
cartilage in mice lacking matrix GLA protein. Nature. 1997;386(6620):78-81.
http://dx.doi.org/10.1038/386078a0
PMid:9052783
21. Meier M, Weng LP, Alexandrakis E,
Ruschoff J, Goeckenjan G. Tracheobronchial stenosis in Keutel syndrome. Eur
Respir J. 2001;17(3):566-9.
http://dx.doi.org/10.1183/09031936.01.17305660
PMid:11405537
22. Kruger T, Oelenberg S, Kaesler N,
Schurgers LJ, van de Sandt AM, Boor P, et al. Warfarin induces cardiovascular
damage in mice. Arterioscler Thromb Vasc Biol. 2013;33(11):2618-24.
http://dx.doi.org/10.1161/ATVBAHA.113.302244
PMid:23990204
23. McCabe KM, Booth SL, Fu X, Shobeiri N,
Pang JJ, Adams MA, et al. Dietary vitamin K and therapeutic warfarin alter the
susceptibility to vascular calcification in experimental chronic kidney
disease. Kidney Int. 2013;83(5):835-44.
http://dx.doi.org/10.1038/ki.2012.477
PMid:23344475
24. Holden RM, Sanfilippo AS, Hopman WM,
Zimmerman D, Garland JS, Morton AR. Warfarin and aortic valve calcification in
hemodialysis patients. J Nephrol. 2007;20(4):417-22.
PMid:17879207
25. Hayashi M, Takamatsu I, Kanno Y,
Yoshida T, Abe T, Sato Y. A case-control study of calciphylaxis in Japanese
end-stage renal disease patients. Nephrol Dial Transplant. 2012;27(4):1580-4.
http://dx.doi.org/10.1093/ndt/gfr658
PMid:22121234
26. Hylek EM, Go AS, Chang Y, Jensvold NG,
Henault LE, Selby JV, et al. Effect of intensity of oral anticoagulation on
stroke severity and mortality in atrial fibrillation. N Engl J Med.
2003;349(11):1019-26.
http://dx.doi.org/10.1056/NEJMoa022913
PMid:12968085
27. Wan Y, Heneghan C, Perera R, Roberts
N, Hollowell J, Glasziou P, et al. Anticoagulation control and prediction of
adverse events in patients with atrial fibrillation: a systematic review. Circ
Cardiovasc Qual Outcomes. 2008;1(2):84-91.
http://dx.doi.org/10.1161/CIRCOUTCOMES.108.796185
PMid:20031794
28. Phelan PJ, O'Kelly P, Holian J, Walshe
JJ, Delany C, Slaby J, et al. Warfarin use in hemodialysis patients: what is
the risk? Clin Nephrol. 2011;75(3):204-11.
http://dx.doi.org/10.5414/CN106481
PMid:21329630
29. Rioux JP, De Bortoli B, Querin S,
Deziel C, Troyanov S, Madore F. Measurement of the international normalized
ratio (INR) in hemodialysis patients with heparin-locked central venous
catheters: evaluation of a novel blood sampling method. J Vasc Access.
2009;10(3):180-2.
PMid:19670171
30. Rombouts EK, Rosendaal FR, Van Der
Meer FJ. Daily vitamin K supplementation improves anticoagulant stability. J
Thromb Haemost: JTH. 2007;5(10):2043-8.
http://dx.doi.org/10.1111/j.1538-7836.2007.02715.x
PMid:17666020
31. Sood MM, Rigatto C, Bueti J, Lang C,
Miller L, PonnamPalam A, et al. Thrice weekly warfarin administration in
haemodialysis patients. Nephrol Dial Transplant. 2009;24(10):3162-7.
http://dx.doi.org/10.1093/ndt/gfp252
PMid:19487735
32. January CT, Wann LS, Alpert JS,
Calkins H, Cigarroa JE, Cleveland JC, et al. 2014 AHA/ACC/HRS Guideline for the
Management of Patients With Atrial Fibrillation: A Report of the American
College of Cardiology/American Heart Association Task Force on Practice
Guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):e199-e267.
http://dx.doi.org/10.1161/CIR.0000000000000041
PMid:24682347
33. K/DOQI clinical practice guidelines
for cardiovascular disease in dialysis patients. Am J Kidney Dis. 2005;45(4
Suppl 3):S1-153.
34. Herzog CA, Asinger RW, Berger AK,
Charytan DM, Diez J, Hart RG, et al. Cardiovascular disease in chronic kidney
disease. A clinical update from Kidney Disease: Improving Global Outcomes
(KDIGO). Kidney Int. 2011;80(6):572-86.
http://dx.doi.org/10.1038/ki.2011.223
PMid:21750584
35. Wang AY, Brimble KS, Brunier G, Holt
SG, Jha V, Johnson DW, et al. ISPD Cardiovascular and Metabolic Guidelines in
Adult Peritoneal Dialysis Patients Part II - Management of Various
Cardiovascular Complications. Perit Dial Int. 2015;35(4):388-96.
http://dx.doi.org/10.3747/pdi.2014.00278
PMid:26228783
36. Wang AY, Brimble KS, Brunier G, Holt
SG, Jha V, Johnson DW, et al. ISPD Cardiovascular and Metabolic Guidelines in
Adult Peritoneal Dialysis Patients Part I - Assessment and Management of
Various Cardiovascular Risk Factors. Perit Dial Int. 2015;35(4):379-87.
http://dx.doi.org/10.3747/pdi.2014.00279
PMid:26228782
37. Juma S, Thomson BK, Lok CE, Clase CM,
Blake PG, Moist L. Warfarin use in hemodialysis patients with atrial
fibrillation: decisions based on uncertainty. BMC Nephrol. 2013;14:174.
http://dx.doi.org/10.1186/1471-2369-14-174
PMid:23941163 PMCid:PMC3751624
38. Chan KE, Lazarus JM, Thadhani R, Hakim
RM. Warfarin use associates with increased risk for stroke in hemodialysis
patients with atrial fibrillation. J Am Soc Nephrol. 2009;20(10):2223-33.
http://dx.doi.org/10.1681/ASN.2009030319
PMid:19713308 PMCid:PMC2754104
39. Winkelmayer WC, Liu J, Setoguchi S,
Choudhry NK. Effectiveness and safety of warfarin initiation in older hemodialysis
patients with incident atrial fibrillation. Clin J Am Soc Nephrol.
2011;6(11):2662-8.
http://dx.doi.org/10.2215/CJN.04550511
PMid:21959598 PMCid:PMC3206003
40. Ray WA. Evaluating medication effects
outside of clinical trials: new-user designs. Am J Epidemiol.
2003;158(9):915-20.
http://dx.doi.org/10.1093/aje/kwg231
PMid:14585769
41. Li J, Wang L, Hu J, Xu G. Warfarin use
and the risks of stroke and bleeding in hemodialysis patients with atrial
fibrillation: A systematic review and a meta-analysis. Nutr Metab Cardiovasc
Dis. 2015;25(8):706-13.
http://dx.doi.org/10.1016/j.numecd.2015.03.013
PMid:26026205
42. Patel MR, Mahaffey KW, Garg J, Pan G,
Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial
fibrillation. N Engl J Med. 2011;365(10):883-91.
http://dx.doi.org/10.1056/NEJMoa1009638
PMid:21830957
43. Granger CB, Alexander JH, McMurray JJ,
Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with
atrial fibrillation. N Engl J Med. 2011;365(11):981-92.
http://dx.doi.org/10.1056/NEJMoa1107039
PMid:21870978
44. Connolly SJ, Ezekowitz MD, Yusuf S,
Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients
with atrial fibrillation. N Engl J Med. 2009;361(12):1139-51.
http://dx.doi.org/10.1056/NEJMoa0905561
PMid:19717844
45. Chan KE, Edelman ER, Wenger JB,
Thadhani RI, Maddux FW. Dabigatran and rivaroxaban use in atrial fibrillation
patients on hemodialysis. Circulation. 2015;131(11):972-9.
http://dx.doi.org/10.1161/CIRCULATIONAHA.114.014113
PMid:25595139
46. Pollack CV, Jr., Reilly PA, Eikelboom
J, Glund S, Verhamme P, Bernstein RA, et al. Idarucizumab for Dabigatran
Reversal. N Engl J Med. 2015;373(6):511-20.
http://dx.doi.org/10.1056/NEJMoa1502000
PMid:26095746
47. Knauf F, Chaknos CM, Berns JS,
Perazella MA. Dabigatran and kidney disease: a bad combination. Clin J Am Soc
Nephrol. 2013;8(9):1591-7.
http://dx.doi.org/10.2215/CJN.01260213
PMid:23868901 PMCid:PMC3805067
48. Wilson JA, Goralski KB, Soroka SD,
Morrison M, Mossop P, Sleno L, et al. An evaluation of oral dabigatran
etexilate pharmacokinetics and pharmacodynamics in hemodialysis. J Clin Pharmacol.
2014;54(8):901-9.
http://dx.doi.org/10.1002/jcph.335
PMid:24846496
49. Kubitza D, Becka M, Mueck W, Halabi A,
Maatouk H, Klause N, et al. Effects of renal impairment on the pharmacokinetics,
pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa
inhibitor. British J Clin Pharmacol. 2010;70(5):703-12.
http://dx.doi.org/10.1111/j.1365-2125.2010.03753.x
PMid:21039764 PMCid:PMC2997310
50. Deal EN, Pope H, Ross W. Apixaban use
among patients with severe renal impairment. Ann Pharmacother.
2014;48(12):1667.
http://dx.doi.org/10.1177/1060028014554446
PMid:25388542
51. Wang X, Tirucherai G, Marbury TC, Wang
J, Chang M, Zhang D, et al. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with
end-stage renal disease on hemodialysis. J Clin Pharmacol. 2015.
http://dx.doi.org/10.1002/jcph.628
PMCid:PMC4418344
52. Hart RG, Pearce LA, Asinger RW, Herzog
CA. Warfarin in atrial fibrillation patients with moderate chronic kidney
disease. Clin J Am Soc Nephrol. 2011;6(11):2599-604.
http://dx.doi.org/10.2215/CJN.02400311
PMid:21903982 PMCid:PMC3359566
53. Palmer SC, Navaneethan SD, Craig JC,
Johnson DW, Perkovic V, Hegbrant J, et al. HMG CoA reductase inhibitors
(statins) for people with chronic kidney disease not requiring dialysis. Cochrane
Database Syst Rev. 2014;5:Cd007784.
http://dx.doi.org/10.1002/14651858.cd007784.pub2
54. Palmer SC, Navaneethan SD, Craig JC,
http://dx.doi.org/10.1002/14651858.cd004289.pub5
55. Sibbald B, Roland M. Understanding
controlled trials. Why are randomised controlled trials important? BMJ.
1998;316(7126):201.
http://dx.doi.org/10.1136/bmj.316.7126.201
PMid:9468688 PMCid:PMC2665449
56. Dentali F, Donadini MP, Clark N,
Crowther MA, Garcia D, Hylek E, et al. Brand name versus generic warfarin: a
systematic review of the literature. Pharmacotherapy. 2011;31(4):386-93.
http://dx.doi.org/10.1592/phco.31.4.386
PMid:21449627